Clinical trials: Digestive System Malignancies
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Post-operative Pneumonia, Lung Cancer
Prevention of Post-operative Pneumonia (POPP)
Postoperative pneumonia is a major complication in patients undergoing thoracic surgery. It leads to considerable morbidity and contributes to perioperative morbidity.
- Conditions
- Post-operative Pneumonia, Lung Cancer, Esophageal Cancer
- Trial name
- POPP (NCT01446874)
- Testing
- 0.12% chlorhexidine solution
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Esophageal Cancer
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
The interaction of epidermal growth factor receptor (EGFR) inhibitory agents such as cetuximab combined with radiation shows promising results.
- Trial name
- NCT00319735
- Testing
- Radiation Therapy, Surgery, Tissue Sample
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Nasser Hanna, M.D.
Metastatic Colorectal Cancer
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
One of the treatments generally used to treat this disease is a chemotherapy called FOLFIRI. The purpose of this study is to improve the efficacy of the chemotherapy by adding a protein, similar to immunoglobulins, aflibercept…
- Trial name
- NCT02181556
- Testing
- FOLFIRI Protocol, Aflibercept Injection
- Where
- 8 sites in France
- Volunteers
- 41 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Neoplasms, Cancer of the Pancreas
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Background: In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- Conditions
- Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer
- Trial name
- NCT01313416
- Testing
- CT-011, Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Augusta University
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02890355
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 783 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver
Fluorodeoxyglucose (FDG) positron emission tomography (PET) is now widely used for cancer imaging purpose, notably for preoperative work-up. It aims at visualizing organs metabolism.
- Trial name
- RespiTEP (NCT01219985)
- Testing
- standard and respiratory-gated PET acquisitions
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Liver Neoplasms, Colonic Neoplasms
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
The purpose of this study is to determine a tolerable dose of radiation delivered by the CyberKnife system in two groups of patients with hepatocellular carcinoma (HCC).
- Conditions
- Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
- Trial name
- NCT01528878
- Testing
- Stereotactic Radiosurgery using the CyberKnife System.
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%)…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03073785
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Carcinoma, Islet Cell, Carcinoma, Pancreas
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received…
- Trial name
- NCT00428597
- Testing
- sunitinib malate
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Colorectal Cancer, Precancerous Condition
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT01011478
- Testing
- rosuvastatin
- Where
- 587 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- NSABP Foundation Inc
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial
This phase I trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-years old) cancer survivors.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8
- Trial name
- E-PROOF (NCT06016725)
- Testing
- Exercise Intervention, Informational Intervention, Nutritional Assessment
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Liver Cancer, Pancreatic Cancer
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
The goal of this clinical research study is to learn if there is a difference in patients' quality of recovery if they receive 1 of 2 standard kinds of pain control treatments after surgery on the liver and/or pancreas.
- Trial name
- NCT01438476
- Testing
- Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Advanced Cancer
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
- Trial name
- NCT03098550
- Testing
- Nivolumab, Daratumumab
- Where
- 20 sites in United States, Australia and 7 more
- Volunteers
- 105 people
- Sponsor
- Bristol-Myers Squibb
Colo-rectal Cancer
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
The aim of this 2-year study will assess the acceptability and feasibility of offering Problem Solving Skills Therapy (PSST) to cancer survivors and their caregivers focusing on the highest risk patients with distress.
- Trial name
- NCT03567850
- Testing
- Problem solving Skills Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT00383760
- Testing
- eribulin mesylate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.